RARE-51. RITUXIMAB, METHOTREXATE, BCNU, ETOPOSIDE, AND PREDNISONE (RMBVP) FOR THE TREATMENT OF RELAPSED/RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE SINGLE CE...

gan Reiss, Samantha, Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Cyhoeddwyd yn Neuro Oncol (2019)

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

gan Reiss, Samantha N., Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Cyhoeddwyd yn J Immunother Cancer (2017)

ACTR-94. TOXICITY OF SINGLE AGENT CARMUSTINE VERSUS CARMUSTINE PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT OR PROGRESSIVE HIGH GRADE GLIOMAS

gan Yerram, Prakirthi, Reiss, Samantha, Modelevsky, Lisa, Gavrilovic, Igor, Kaley, Thomas
Cyhoeddwyd yn Neuro Oncol (2017)

Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas

gan Yerram, Prakirthi, Reiss, Samantha N, Modelevsky, Lisa, Gavrilovic, Igor T, Kaley, Thomas
Cyhoeddwyd yn J Neurooncol (2019)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

gan Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Cyhoeddwyd yn CNS Oncol (2018)

Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City

gan Yerram, Prakirthi, Thackray, Jennifer, Modelevsky, Lisa R, Land, Josiah D, Reiss, Samantha N, Spatz, Krisoula H, Levoir, Andrea C, Pak, Terry K, Dao, Phuong H, Buege, Michael J, Derespiris, Lauren M, Lau, Carmen, Orozco, Jennifer S, Boparai, Manpreet, Koranteng, Lauren A, Reichert, Kate E, Yan, Shirley Q, Daukshus, Nicole P, Mathew, Sherry, Buie, Larry W, Tizon, Richard F, Freeswick, Scott, Liu, Dazhi, Harnicar, Stephen
Cyhoeddwyd yn J Oncol Pharm Pract (2021)